Valproate, in combination with pemetrexed and cisplatin, provides additional efficacy to the treatment of malignant mesothelioma.
Fiche publication
Date publication
avril 2009
Journal
Clinical cancer research : an official journal of the American Association for Cancer Research
Auteurs
Membres identifiés du Cancéropôle Est :
Pr MASCAUX Céline
Tous les auteurs :
Vandermeers F, Hubert P, Delvenne P, Mascaux C, Grigoriu B, Burny A, Scherpereel A, Willems L
Lien Pubmed
Résumé
Present chemotherapeutic regimens are marginally efficient in tumor cells being particularly resistant to radiotherapy and/or chemotherapy. We hypothesized that unresponsiveness of tumors to conventional therapeutic agents might be due to inappropriate gene expression resulting from epigenetic modifications and leading to transcriptional silencing. The goal of this study was to evaluate the anticancer effect of a histone deacetylase inhibitor, valproate, on mesothelioma cells in combination with pemetrexed and cisplatin, the usual first-line regimen of chemotherapy for this tumor.
Mots clés
Animals, Antineoplastic Agents, pharmacology, Antineoplastic Combined Chemotherapy Protocols, Apoptosis, drug effects, BH3 Interacting Domain Death Agonist Protein, drug effects, Caspase 8, metabolism, Cell Line, Tumor, Cell Survival, drug effects, Cisplatin, pharmacology, Cyclin-Dependent Kinase Inhibitor p21, agonists, Cytochromes c, drug effects, Drug Synergism, Enzyme Inhibitors, pharmacology, Glutamates, pharmacology, Guanine, analogs & derivatives, Histones, drug effects, Humans, Mesothelioma, drug therapy, Mice, Mice, Inbred BALB C, Mice, SCID, Mitochondria, drug effects, Pemetrexed, Reactive Oxygen Species, metabolism, Valproic Acid, pharmacology
Référence
Clin. Cancer Res.. 2009 Apr 15;15(8):2818-28